Seattle-based Mozart Therapeutics closed on a $55 million Series A financing round, led by seed financier ARCH Venture Partners along with Sofinnova Partners. Additional investors were Eli Lilly and Company, MRL Ventures Fund, an early-stage fund run by Merck & Co., Leaps by Bayer, Altitude Life Science Ventures, and Alexandria Venture Investments.
Three years after Takeda Pharmaceutical and PvP Biologics inked a $35 million deal to develop a novel treatment for celiac disease, the Japanese pharma manufacturer exercised an option to acquire the San Diego-based company for $330 million.
GlaxoSmithKline will acquire San Diego-based Sitari Pharmaceuticals and the company’s transglutaminase 2 small molecule program for celiac disease.
For people with celiac disease, even tiny amounts of gluten in foods can cause trouble, and restaurants may be the hardest places to avoid the hidden protein, a U.S. study suggests.
A definitive merger agreement was signed under which the shareholders of privately held Innovate Biopharmaceuticals Inc. will become the majority owners of Monster Digital Inc. Subject to shareholder approval, the combined company will advance a late-stage drug for celiac disease, which Innovate believes is a significant unmet medical need, into expected Phase 3 clinical trials.
Newport Beach, CA — March 15, 2016 Glutenase for in-vivo gluten degradation is a leading candidate for celiac disease ImmunogenX™, a biopharmaceutical company focused on the diagnosis and treatment […]
